NEOGENOMICS INC : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events (form 8-K)

Item 1.01 Entry into a Definitive Agreement.

On January 10, 2020, NeoGenomics Laboratories, Inc. ("NeoGenomics Labs"), a wholly-owned subsidiary of NeoGenomics, Inc. ("NeoGenomics", the "Company") and Human Longevity, Inc. ("HLI") entered into an Asset Purchase Agreement ("APA") pursuant to which NeoGenomics Labs acquired substantially all the assets of the oncology division of HLI for $37 million in cash. The APA contains representations, warranties, covenants and agreements that the Company believes are customary for transactions of this type.

The forgoing description of the terms of the APA does not purport to be complete and is qualified in its entirety by reference to the provisions of such agreement, which is filed as Exhibit 2.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 2.01   Completion of Acquisition or Disposition of Assets.

The disclosures set forth in Item 1.01 of this Current Report on Form 8-K are incorporated by reference into this Item 2.01.

Item 8.01   Other Events.

On January 10, 2020, the Company issued a press release announcing the acquisition of the oncology division of HLI.

A copy of the press release is furnished herewith as Exhibit 99.1 to the Current Report on Form 8-K.

Item 9.01   Exhibits.

(d) Exhibits.

2.1 Asset Purchase Agreement , dated January 10, 2020 , by and among Human Longevity, Inc. and NeoGenomics

Laboratories , Inc.

99.1 Press R elease dated January 10, 2020.

© Edgar Online, source Glimpses